Most Favored Nation drug pricing, TrumpRx, and record drug-price drop
Advancing
Dr. Mehmet Oz has made drug affordability a signature of his CMS tenure, pointing to Most Favored Nation pricing deals that aim to align U.S. drug prices with the lowest developed-nation rates, and promoting the TrumpRx platform for discounted cash prices (including GLP-1 medications).
Oz cites a 3.1% annual prescription-drug price decline for the year ending July 2026 — what he called “the largest drop in pharmaceutical drug prices for consumers in 63 years,” in remarks at a September 9, 2026 RNC event reported by realtruth.media. The administration attributes the decline to the MFN pricing deals. The Bloomberg interview corroborates Oz’s push for Congress to codify the MFN arrangements.
A source-quality note: the RNC-event quotes come via realtruth.media, a partisan outlet; the Bloomberg “Balance of Power” interview independently corroborates the MFN-codification push.
Timeline
- September 9, 2026 — Oz tells Bloomberg’s “Balance of Power” that Treasury-identified suspected fraud could extend the Medicare trust fund’s life and calls on Congress to codify MFN drug-pricing deals. (Bloomberg)
- September 9, 2026 — Oz cites a 3.1% annual prescription-drug price decline (year ending July 2026) at an RNC event, calling it “the largest drop in pharmaceutical drug prices for consumers in 63 years.” (realtruth.media)
